Literature DB >> 12014632

Overexpression of cyclin DI contributes to malignant properties of esophageal tumor cells by increasing VEGF production and decreasing Fas expression.

Masafum Shintani1, Aki Okazaki, Tohru Masuda, Manabu Kawada, Masaaki Ishizuka, Yuichiro Doki, I Bernard Weinstein, Masaya Imoto.   

Abstract

Cyclin D1 is frequently overexpressed in human esophageal cancer. We examined the possible role of cyclin D1 overexpression on specific malignant properties of tumor cells using a series of eight human esophageal cancer cell lines that express different levels of cyclin D1. We did not find a simple correlation between levels of cyclin D1 expression and anchorage-independent growth, production of angiogenic factors, or tumorigenicity in nude mice, suggesting that other factors can influence these parameters. We did, however, obtain evidence that tumorigenicity appeared to require both the capacity for anchorage-independent growth and the production of angiogenic factors. To better assess the specific role of cyclin D1, we stably expressed an antisense cyclin D1 cDNA construct in the tumorigenic cell line TTn. This significantly decreased anchorage-independent growth and VEGF production and led to a loss of tumorigenicity in nude mice. Furthermore, these cells diplayed a marked increase in sensitivity to antitumor agents and to Fas antibody-induced apoptosis. Taken together, these findings suggest that the overexpression of cyclin D1 can confer esophageal cancer cells with enhanced malignancy through increases in anchorage-independent growth and VEGF production, and down-regulation of Fas expression, thus suggesting novel functions of the cyclin D1 protein in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12014632

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

Review 1.  Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.

Authors:  L Pignataro; G Sambataro; D Pagani; G Pruneri
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

Review 2.  Uterine myxoid leiomyosarcoma - a rare malignant tumor: the role of complex morphopathological assay. Review and case presentation.

Authors:  Anca Maria Istrate-Ofiţeru; George Lucian Zorilă; Dan Ruican; Ana Maria Petrescu; Elena Iuliana Anamaria Berbecaru; Gabriela Camelia Roşu; Răzvan Grigoraş Căpitănescu; Rodica Daniela Nagy; Liliana Cercelaru; Antonie Edu; Dominic Gabriel Iliescu; Roxana Cristina Drăguşin
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

3.  Curcumin inhibits human non-small cell lung cancer xenografts by targeting STAT3 pathway.

Authors:  Xiaofang Xu; Yuping Zhu
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

4.  Juxtaglomerular cell tumor: Clinical and immunohistochemical features.

Authors:  Fen Wang; Chuan Shi; Yunying Cui; Chunyan Li; Anli Tong
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-03-20       Impact factor: 3.738

5.  Therapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer.

Authors:  Jin-Hee Seo; Eui-Suk Jeong; Yang-Kyu Choi
Journal:  BMC Cancer       Date:  2014-03-11       Impact factor: 4.430

6.  Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia.

Authors:  Sajjad Karim; Jaudah A Al-Maghrabi; Hasan M A Farsi; Ahmad J Al-Sayyad; Hans-Juergen Schulten; Abdelbaset Buhmeida; Zeenat Mirza; Alaa A Al-Boogmi; Fai T Ashgan; Manal M Shabaad; Hend F NourEldin; Khalid B M Al-Ghamdi; Adel Abuzenadah; Adeel G A Chaudhary; Mohammed H Al-Qahtani
Journal:  BMC Cancer       Date:  2016-09-30       Impact factor: 4.430

7.  Inhibition of PHLPP2/cyclin D1 protein translation contributes to the tumor suppressive effect of NFκB2 (p100).

Authors:  Jiawei Xu; Yulei Wang; Xiaohui Hua; Jiheng Xu; Zhongxian Tian; Honglei Jin; Jingxia Li; Xue-Ru Wu; Chuanshu Huang
Journal:  Oncotarget       Date:  2016-06-07

Review 8.  Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy.

Authors:  Byeong Mo Kim; Yunkyung Hong; Seunghoon Lee; Pengda Liu; Ji Hong Lim; Yong Heon Lee; Tae Ho Lee; Kyu Tae Chang; Yonggeun Hong
Journal:  Int J Mol Sci       Date:  2015-11-10       Impact factor: 5.923

9.  Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor.

Authors:  Gabrielle Karpinsky; Malgorzata A Krawczyk; Ewa Izycka-Swieszewska; Aleksandra Fatyga; Agnieszka Budka; Walentyna Balwierz; Grazyna Sobol; Beata Zalewska-Szewczyk; Magdalena Rychlowska-Pruszynska; Teresa Klepacka; Bozenna Dembowska-Baginska; Bernarda Kazanowska; Anna Gabrych; Ewa Bien
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-13       Impact factor: 4.553

10.  Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway.

Authors:  Xin Rui; Hua-Feng Pan; Si-Liang Shao; Xiao-Ming Xu
Journal:  BMC Complement Altern Med       Date:  2017-08-01       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.